Splanchnic vein thrombosis in myeloproliferative neoplasms

British Journal of Haematology

Volumn 162, Issue 6, 2013, Pages 730-747

  Sekhar, Mallika ^a   Mcvinnie, Kathryn ^b   Burroughs, Andrew K ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Essential thrombocythaemia; Myelofibrosis; Myeloproliferative neoplasm; Polycythaemia vera; Spleen; Thrombosis (venous)

Indexed keywords

HEMOSTATIC AGENT; JANUS KINASE 2;

ABNORMAL LABORATORY RESULT; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLOOD CELL; BLOOD CELL COUNT; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD FLOW; CANCER STAGING; CLINICAL FEATURE; COMORBIDITY; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE PREDISPOSITION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EPIDEMIOLOGICAL DATA; GENE; GENE MUTATION; GENETIC DISORDER; HAPLOTYPE; HEMODYNAMICS; HUMAN; JAK2 GENE; LIFE EXPECTANCY; LIVER CIRRHOSIS; LUNG EMBOLISM; MYELOPROLIFERATIVE NEOPLASM; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SPLANCHNIC BLOOD FLOW; SPLANCHNIC VEIN THROMBOSIS; SPLEEN; SPLENOMEGALY; SUPERFICIAL THROMBOPHLEBITIS; SURVIVAL PREDICTION; THROMBOPHILIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TUMOR MICROENVIRONMENT; VEIN THROMBOSIS;

ESSENTIAL THROMBOCYTHAEMIA; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHAEMIA VERA; SPLEEN; THROMBOSIS (VENOUS);

AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; SPLANCHNIC CIRCULATION; VENOUS THROMBOSIS;

EID: 84883273483     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12461     Document Type: Review

References (146)

1. Ageno, W., Squizzato, A., Togna, A., Magistrali, F., Mangini, M., Fugazzola, C. & Dentali, F. (2011) Incidental diagnosis of deep vein thrombosis in consecutive patients undergoing a computer tomography scan of the abdomen: a retrospective cohort study. Journal of Thrombosis and Haemostasis, 10, 158-160.
2. Ageno, W., Riva, N., Bang, S.-M., Sartori, M.T., Grandone, E., Beyer-Westendorf, J., Barillari, G., De Minno, M.N.D., Duce, R., Malato, A., Santoro, R., Poli, D., Verhamme, P., Martinell, I., Kamphuisen, P.W., Alatri, A., Oh, D., Amico, E.D., Schulman, S. & Dentali, F. (2012) Antithrombotic treatment of splanchnic vein thrombosis: results of an International Registry. Blood (ASH Annual Meeting Abstracts), 120, abstract 499.
3. Aird, W.C. (2007a) Vascular bed-specific thrombosis. Journal of Thrombosis & Haemostasis, 5, 283-291.
4. Aird, W.C. (2007b) Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circulation Research, 100, 174-190.
5. Alvarez-Larrán, A., García-Pagán, J.C., Abraldes, J.G., Arellano, E., Reverter, J.C., Bosch, J. & Cervantes, F. (2004) Increased CD11b in neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. British Journal of Haematology, 124, 329-335.
6. Alvarez-Larrán, A., Arellano-Rodrigo, E., Reverter, J.C., Domingo, A., Billamor, N., Colomer, D. & Cervantes, F. (2008) Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Annals of Hematology, 87, 269-276.
7. Alvarez-Larrán, A., Bellosillo, B., Martínez-Avíles, L., Saumell, S., Salar, A., Abella, E., Gimeno, E., Serrano, S., Florensa, L., Sánchez, B., Pedro, C. & Besses, C. (2009) Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. British Journal of Haematology, 146, 504-509.
8. Amitrano, L., Guardascione, M.A., Ames, P.R.J., Margaglione, M., Antinolfi, I., Iannaccone, L., Annunziata, M., Ferrara, F., Brancaccio, V. & Balzano, A. (2003) Thrombophilic genotypes, natural anticoagulants and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. American Journal of Hematology, 72, 75-81.
9. Amitrano, L., Guardascione, M.A., Scaglione, M., Pezzullo, L., Sangiuliano, N., Armellino, M.F., Manguso, F., Margaglione, M., Ames, P.R., Iannaccone, L., Grandone, E., Romano, L. & Balzano, A. (2007) Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. American Journal of Gastroenterology, 102, 2464-2470.
10. Arellano-Rodrigo, E., Alvarez-Larrán, A., Reverter, J.C., Villamor, N., Colomer, D. & Cervantes, F. (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica, 91, 169-175.
11. Arellano-Rodrigo, E., Alvarez-Larrán, A., Reverter, J.C., Colomer, D., Villamor, N., Bellosillo, B. & Cervantes, F. (2009) Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. American Journal of Hematology, 84, 102-108.
12. Attwell, A., Ludkowski, M., Nash, R. & Kugelmas, M. (2004) Treatment of Budd-Chiari syndrome in a Liver Transplant Unit, role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Alimentary Pharmacology & Therapeutics, 20, 867-873.
13. Barbui, T., Carobbio, A., Cervantes, F., Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Alvarez-Larrán, A., Rambaldi, A., Finazzi, G. & Barosi, G. (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 115, 778-782.
14. Barbui, T., Thiele, J., Carobbio, A., Passamonti, F., Rumi, E., Randi, L.M., Bertozzi, I., Vannucchi, A.M., Gisslinger, H., Bisslinger, B., Finazzi, G., Ruggeri, M., Rodehiero, F., Rambaldi, A., Gangat, N. & Tefferi, A. (2012) Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood, 120, 569-571.
15. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
16. Bayraktar, Y., Harmanci, O., Buyukasik, Y., Shorbagi, A.I., Sungur, A.H., Boylu, C.A., Gurgey, A. & Balkanci, F. (2008) JAK2V617F mutation in patients with portal vein thrombosis. Digestive Diseases and Sciences, 52, 2779-2783.
17. Bazzan, M., Tamponi, G., Schinco, P., Vaccarino, A., Foli, C., Galone, G. & Pileri, A. (1999) Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Annals of Haematology, 78, 539-543.
18. Bellucci, S., Cassinat, B., Bonnin, N., Marzac, C. & Crassard, I. (2008) The V617F JAK2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorders. Thrombosis and Haemostasis, 99, 1119-1120.
19. Bench, A.J., White, H.E., Foroni, L., Godfrey, A.L., Gerrard, G., Akiki, S., Awan, A., Carter, I., Goday-Fernandez, A., Langabeer, S.E., Clench, T., Clark, J., Evans, P.A., Grimwade, D., Schuh, A., McMullin, M.F., Green, A.R., Harrison, C.N. & Cross, N.C. (2013) Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. British Journal of Haematology, 160, 25-34.
20. Besses, C., Cervantes, F., Pereira, A., Florensa, L., Solé, F., Hernández-Boluda, J.C., Woessner, S., Sans-Sabrafen, J., Rozman, C. & Montserrat, E. (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia, 13, 150-154.
21. Boissinot, M., Lippert, E., Girodon, F., Dobo, I., Fouassier, M., Masliah, C., Praloran, V. & Hermouet, S. (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood, 108, 3223-3224.
22. Campbell, P.J., Scott, L.M., Buck, G., Weatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.R., Harrison, C.N. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945-1953.
23. Campbell, P.J., MacLean, C., Beer, P.A., Buck, G., Wheatley, K., Kiladjian, J.J., Forsyth, C., Harrison, C.N. & Green, A.R. (2012) Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood, 120, 1409-1411.
24. Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A. & Barbui, T. (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 109, 2310-2313.
25. Carobbio, A., Antonioli, E., Guglielmelli, P., Vannucchi, A.M., Delaini, F., Guerini, V., Finazzi, G., Rambaldi, A. & Barbui, T. (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. Journal of Clinical Oncology, 26, 2732-2736.
26. Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M.L., Bertozzi, I., Vannucchi, A.M., Antonioli, E., Gisslinger, H., Buxhofer-Ausch, V., Finazzi, G., Gangat, N., Tefferi, A. & Barbui, T. (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood, 117, 5857-5859.
27. Cella, G., Marchetti, M., Vianello, F., Panova-Noeva, M., Vignoli, A., Russo, L., Barbui, T. & Falanga, A. (2010) Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 104, 151-156.
28. Chim, C.S., Kwong, Y.L., Lie, A.K.W., Ma, S.K., Chan, C.C., Wong, L.G., Kho, B.C.S., Lee, H.K., Sim, J.P.Y., Chan, C.H., Chan, J.C.W., Yeung, Y.M., Law, M. & Liang, R. (2005) Long-term outcome of 213 patients with essential thrombocythemia. Archives of Internal Medicine, 165, 2651-2658.
29. Colaizzo, D., Amitrano, L., Tiscia, G.L., Scenna, G., Grandone, E., Guardascione, M.A., Brancaccio, V. & Margaglione, M. (2007) The JAK2 V617F mutation frequency occurs in patients with portal and mesenteric venous thrombosis. Journal of Thrombosis and Haemostasis, 5, 55-61.
30. Colaizzo, D., Amitrano, L., Tiscia, G.L., Iannaccone, L., Ballone, A., Grandone, E., Guardascione, M.A. & Margaglione, M. (2008) Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagulation & Fibrinolysis, 19, 459-462.
31. Colaizzo, D., Tiscia, G.L., Bafunno, V., Amitrano, L., Vergura, P., Lupone, M.R., Grandone, E., Guardascione, M.A. & Margaglione, M. (2011) Sex modulation of the occurrence of JAK2 V617F mutation in patients with splanchnic venous thrombosis. Thrombosis Research, 189, 233-236.
32. Colombi, M., Radaelli, F., Zocchi, L. & Maiolo, A.T. (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. Cancer, 67, 2926-2930.
33. Condat, B., Pessione, F., Hillaire, S., Denninger, M.-H., Guillin, M.-C., Poliquin, M., Hadengue, A., Erlinger, S. & Valla, D. (2001) Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology, 120, 490-497.
34. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. & Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology, 8, 556-562.
35. Darwish Murad, S., Valla, D.C., de Groen, P.C., Zeitoun, G., Hopmans, J.A.M., Haagsma, E.B., van Hoek, B., Hansen, B.E., Rosendaal, F.R. & Janssen, H.L.A. (2004) Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology, 39, 500-508.
36. Darwish Murad, S., Plessier, A., Hernandez-Guerra, M., Fabris, F., Eapen, C.E., Bahr, M.J., Trebicka, J., Morard, I., Lasser, L., Heller, J., Handengue, A., Langlet, P., Miranda, H., Primignani, M., Elias, E., Leebeek, F.W., Rosendaal, F.R., Garcia Pagan, J.-C., Valla, D.C. & Janssen, H.L.A. (2009) Etiology, management, and outcome of the Budd-Chiari syndrome. Annals of Internal Medicine, 151, 167-175.
37. De Grandis, M., Cambot, M., Wautier, M.P., Cassinat, B., Chomienne, C., Colin, Y., Wautier, J.L., Le Van Kim, C. & El Nemer, W. (2013) JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood, 121, 658-665.
38. De Stefano, V., Chiusolo, P., Paciaroni, K. & Leone, G. (1998) Epidemiology of factor V Leiden: clinical implications. Seminars in Thrombosis and Haemostasis, 24, 367-379.
39. De Stefano, V., Fiorini, A., Rossi, E., Za, T., Farina, G., Chiusolo, P., Sica, S. & Leone, G. (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. Journal of Thrombosis and Haemostasis, 5, 708-714.
40. De Stefano, V., Za, T., Rossi, E., Vannucchi, A.M., Ruggeri, M., Elli, E., Mico, C., Tieghi, A., Cacciola, R.R., Santoro, C., Gerli, G., Vianelli, N., Guglielmelli, P., Pieri, L., Scognamiglio, F., Rodeghiero, F., Pogliani, E.M., Rinazzi, G., Gugliotta, L., Marchioli, R., Leone, G. & Barbui, T. (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors and effect of treatments. Haematologica, 93, 372-380.
41. De Stefano, V., Za, T., Rossi, E., Fiorini, A., Ciminello, A., Luzzi, C., Chiusolo, P., Sica, S. & Leone, G. (2009) The influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica, 94, 733-737.
42. De Stefano, V., Rossi, E., Za, T., Ciminello, A., Betti, S., Luzzi, C., Leone, G. & Chiusolo, P. (2011) JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic of cerebral vein thrombosis. American Journal of Hematology, 86, 526-528.
43. DeLeve, L.D., Valla, D.C. & Garcia-Tsao, G. (2009) Vascular disorders of the liver. Hepatology, 49, 1729-1764.
44. Deltenre, P., Denninger, M.-H., Hillaire, S., Guillin, M.-C., Casadevall, N., Briere, J., Erlinger, S. & Valla, D.-C. (2001) Factor V Leiden related Budd-Chiari syndrome. Gut, 48, 24-268.
45. Denninger, M.-H., Chait, Y., Casadevall, N., Hillaire, S., Guillin, M.-C., Bezeaud, A., Erlinger, S., Briere, J. & Valla, D. (2000) Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology, 31, 587-591.
46. Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A.M. & Ageno, W. (2009) JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood, 113, 5617-5623.
47. Dubois, A., Dauzat, M., Pignodel, C., Pomier-Layrargues, G., Marty-Double, C., Lopez, F.M. & Janbon, C. (1993) Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations. Hepatology, 17, 246-250.
48. Duchemin, J., Ugo, V., Ianotto, J.-C., Lecucq, L., Mercier, B. & Abbrall, J.-F. (2010) Increased circulating procoagulant activity and thrombin geneeration in patients with myeloproliferative neoplasms. Thrombosis Research, 126, 238-242.
49. Elliott, M.A., Pardanani, A., Lasho, T.L., Schwager, S.M. & Terreri, A. (2010) Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica, 95, 1788-1791.
50. Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., Russo, L., Guerini, V. & Barbui, T. (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules. Experimental Hematology, 35, 702-711.
51. Fenaux, P., Simon, M., Caulier, M.T., Lai, J.L., Goudemand, J. & Bauters, F. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer, 66, 549-556.
52. Finazzi, G. & Barbui, T. (2005) Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Reviews, 19, 243-252.
53. Finazzi, G., Gregg, X.T., Barbui, T. & Prchal, J.T. (2006) Idiopathic erythrocytosis and other non-clonal polycythemias. Best Practice & Research. Clinical Haematology, 19, 471-482.
54. Grandone, E., Colaizzo, D., Tiscia, G.L., Vergura, P., Chinni, E., Iannaccone, L., Antinolfi, I., Guardascione, M.A. & Margaglione, M. (2008) Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation. Thrombosis and Haemostasis, 99, 640-642.
55. Grupo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Annals of Internal Medicine, 123, 656-664.
56. Harris, W. & Marcaccio, M. (2005) Incidence of portal vein thrombosis after laparoscopic splenectomy. Canadian Journal of Surgery, 48, 352-354.
57. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. & Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33-45.
58. Hassn, A.M.F., Al-Fallouji, M.A., Ouf, T.I. & Saad, R. (2000) Portal vein thrombosis following splenectomy. British Journal of Surgery, 87, 362-373.
59. Hoekstra, J., Bresser, E.L., Smalberg, H.J., Spaander, M.C.S., Leebeek, F.S.G. & Hanssen, H.L.A. (2011) Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. Journal of Thrombosis and Haemostasis, 9, 2208-2214.
60. Ikeda, M., Sekimto, M., Takiguchi, S., Kubota, M., Masakazu, I., Yamamoto, H., Fujiwara, Y., Ohue, M., Yasuda, T., Imamura, H., Tatsuta, M., Yano, M., Furukawa, H. & Monden, M. (2005) High incidence of thrombosis of the portal venous system after laparoscopic splenectomy. Annals of Surgery, 241, 208-216.
61. Jadli, A., Kulkarni, B., Gosh, K. & Shetty, S. (2012) Non conventional mutations associated with myeloproliferative disorders are absent in splanchnic venous thrombosis cases. Liver International, 32, 1596-1597.
62. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
63. Janssen, H.L., Meinardi, J.R., Vleggaar, F.P., van Uum, S.H., Haagsmas, E.B., van Der Meer, F.J., van Hattum, J., Chamuleau, R.A., Adang, R.P., Vandenbroucke, J.P., van Hoek, B. & Rosendaal, F.R. (2000) Factor V Leiden mutation, prothrombin gene mutation, and defriciencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood, 96, 2364-2368.
64. Janssen, H.L.A., Wijnhoud, A., Haagsma, E.B., Van Uum, S.H.M., van Nieuwkerk, C.M.J., Adang, R.P., Chamuleau, R.A.F.M., van Hattum, J., Vleggaar, F.P., Hansen, B.E., Rosendaal, F.R. & van Hoek, B. (2001) Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut, 49, 720-724.
65. Jantunen, R., Juvonen, E., Ikkala, E., Oksanen, K., Anttila, P. & Ruutu, T. (2001) The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Annals of Hematology, 80, 74-78.
66. Jensen, M.K., de Nully Brown, P., Nielsen, O.J. & Hasselbalch, H.C. (2000) Incidence, clinical features and outcomes of essential thrombocythaemia in a well defined geographical area. European Journal of Haematology, 65, 132-139.
67. Jones, A.V., Chase, A., Silver, R.T., Oscier, D., Zoi, K., Wang, Y.L., Cario, H., Pahl, H.L., Collins, A., Reiter, A., Grand, F. & Cross, N.C. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics, 41, 446-449.
68. Khuroo, M.S., Al-Suhabani, H., Al-Sebayel, M., Al Ashgar, H., Dahab, S., Khan, M.Q. & Khalaf, H.A. (2005) Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. Journal of Gastroenterology and Hepatology, 20, 1494-1502.
69. Kiladjian, J.J., Certantes, F., Leebeed, F.W.G., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatern, D., Plessier, A., Garcia-Pagan, J.-C., Murad, S.D., Raffa, S., Janssen, H.L.A., Gardin, C., Cereja, S., Tonetti, C., Giraudier, S., Condat, B., Casadevall, N., Fenaux, P. & Valla, D.C. (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood, 111, 4922-4929.
70. Kouroupi, E., Kiladijan, J.-J., Chomienne, C., Dosquet, C., Bellucci, S., Valla, D. & Cassinat, B. (2011) The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood, 117, 5777-5778.
71. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779-1790.
72. Landolf, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. & Barbui, T. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114-124.
73. Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R.M., Tognoni, G. & Marchioli, R. (2007) Leukocytosis as a major thrombotic factor in patients with polycythemia vera. Blood, 109, 2446-2452.
74. Landolfi, R., Di Gennaro, L., Nicolazzi, M.S., Giarretta, I., Marfisi, R.M. & Marchioli, R. (2012) Polycythemia vera: gender-related phenotypic differences. Internal and Emergency Medicine, 7, 509-515.
75. Lataillade, J.J., Pierre-Louis, O., Hasselbalch, H.C., Uzon, G., Jasmin, C., Martyre, M.C. & Le Bousse-Kerdiles, M.C. (2008) Does myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood, 112, 3026-3035.
76. Lauw, M.N., Bus, E.W.N., van Wulfften Palthe, A.F.Y., Coppens, M., Homburg, C.H., Middeldorp, S., van der Schoot, C.E., Koene, H.R. & Biemond, B.J. (2012) Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. Annals of Haematology, 91, 103-107.
77. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Hungly, B.J.P., Boggon, T.J., Wlodarska, L., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.F., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
78. Mahmoud, A.E., Elias, E., Beauchamp, N. & Wilde, J.T. (1997) Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut, 40, 798-800.
79. Malak, S., Labopin, M., Saint-Martin, C., Bellanne-Chantelot, C. & Najman, A. (2012) Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells, Molecules, and Diseases, 49, 170-176.
80. Marchetti, M., Castoldi, E., Spronk, H.M.H., van Oerle, R., Balducci, D., Barbui, T., Rosing, J., ten Cate, H. & Falanga, A. (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 112, 4061-4068.
81. Marchioli, R., Finazzi, G., Ladolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G. & Barbui, T. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology, 23, 2224-2232.
82. McMahon, C., Abu-Elmagd, K., Bontempo, F.A., Kant, J.A. & Swerdlow, S.H. (2007) JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. American Journal of Clinical Pathology, 127, 736-743.
83. Melear, J.M., Goldstein, R.M., Levy, M.F., Molmenti, E.P., Cooper, B., Netto, G.J., Klintmalm, G.B. & Stone, M.J. (2002) Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation, 74, 1090-1095.
84. Mohanty, D., Shetty, S., Ghosh, K., Pawar, A. & Abraham, P. (2001) Hereditary thrombophilia as a cause of Budd-Chiari Syndrome: a study from Western India. Hepatology, 34, 666-670.
85. Musolino, C., Allegra, A., Saija, A., Alonci, A., Russo, S., Spatari, G., Penna, G., Gerace, D., Cristani, M., David, A., Saitta, S. & Gangemi, S. (2012) Changes in advanced oxidation protein products, advanced glycatgion end products, and s-nitrosylated proteins in patients affected by polycythemia vera and essential thrombocythemia. Clinical Biochemistry, 45, 1439-1443.
86. Ögren, M., Bergqvist, D., Björck, M., Acosta, S., Eriksson, H. & Sternby, N.H. (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23 796 consecutive autopsies. World journal of gastroenterology, 12, 2115-2119.
87. Olcaydu, D., Harutyunyan, A., Jager, R., Berg, T., Gisslinger, B. & Kralovics, R. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics, 41, 450-454.
88. Orr, D.W., Harrison, P.M., Devlin, J., Karani, J.B., Kane, P.A., Heaton, N.D., O'Grady, J.G. & Heneghan, M.A. (2007) Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clinical Gastroenterology and Hepatology, 5, 80-86.
89. Orr, D.W., Patel, R.K., Lea, N.C., Westbrook, R.H., O'Grady, J.G., Heaton, N.D., Pagliuca, A., Mufti, G.J. & Heneghan, M.A. (2010) The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Alimentary Pharmacology & therapeutics, 31, 1330-1336.
90. Panova-Noeva, M., Marchetti, M., Spronk, H.M., Rusoo, L., Diani, E., Finazzi, G., Salmoiraghi, S., Rambaldi, A., Barbui, T., Ten Cate, H. & Falanga, A. (2011a) Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. American Journal of Hematology, 86, 337-342.
91. Panova-Noeva, M., Marchetti, M., Buoro, S., Russo, L., Leuzzi, A., Finazzi, G., Rambaldi, A., Ottomano, C., Ten Cate, H. & Falanga, A. (2011b) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood, 118, 2599-2601.
92. Papadakis, E., Hoffman, R. & Brenner, B. (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood Reviews, 24, 227-232.
93. Passamonti, F., Malabarba, L., Orlandi, E., Pascutto, C., Brusamoline, E., Astori, E., Barate, C., Canevari, A., Corso, A., Bernasconi, P., Cazzola, M. & Lazzarino, M. (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. British Journal of Haematology, 116, 855-861.
94. Passamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Bursamolino, E., Pascutto, C., Cazzola, M., Morra, E. & Lazzarino, M. (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. The American Journal of Medicine, 117, 755-761.
95. Passamonti, F., Rumi, E., Arcaini, L., Boveri, E., Elena, C., Pietra, D., Boggi, S., Astori, C., Bernasconi, P., Varettoni, M., Brusamolino, E., Pascutto, C. & Lazzarino, M. (2008) Prognostic factors for thrombosis, myelofibrosis, leukaemia in essential thrombocythemia: a study of 605 patients. Haematologica, 93, 1645-1651.
96. Passamonti, S.M., Biguzzi, E., Cazzola, M., Franchi, F., Gianniello, F., Bucciarelli, P., Pietra, D., Mannucci, P.M. & Martinelli, I. (2012) The JAK2 V617F mutation in patients with cerebral venous thrombosis. Journal of Thrombosis and Haemostasis, 10, 998-1003.
97. Patel, R.K., Lea, N.C., Heneghan, M.A., Westwood, N.B., Miljokovic, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gaken, J., Wendon, J., Heaton, N.G. & Mufti, G.J. (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology, 130, 2031-2038.
98. Pearson, T.C. & Wetherley-Mein, G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet, 2, 1219-1222.
99. Perarnau, J.-M. & Bacq, Y. (2008) Hepatic vascular involvement related to pregnancy, oral contraceptives and estrogen replacement therapy. Seminars in Liver Disease, 28, 315-327.
100. Petit, P., Bret, P.M., Atri, M., Hreno, A., Casola, G. & Gianfelice, D. (1994) Splenic vein thrombosis after splenectomy: frequency and role of imaging. Radiology, 190, 65-68.
101. Piaggio, G., Rosti, V., Corselli, M., Bertolotti, F., Bergamaschi, G., Pozzi, S., Imperiale, D., Chiavarina, B., Bonetti, E., Novara, F., Sessarega, M., Villani, L., Garuti, A., Massa, M., Ghio, R., Campanelli, R., Bacigalupo, A., Pecci, A., Viarengo, G., Zuffardi, O., Grassoni, F. & Barosi, G. (2009) Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood, 114, 3127-3130.
102. Pietrabissa, A., Moretto, C., Antonelli, G., Morelli, L., Marciano, E. & Mosca, F. (2004) Thrombosis in the portal venous system after elective laparoscopic splenectomy. Surgical Endoscopy and Other Interventional Techniques, 18, 1140-1143.
103. Plessier, A., Darwish-Murad, S., Hernandez-Guerra, M., Consigny, Y., Fabris, F., Trebicka, J., Heller, J., Morard, I., Lasser, L., Langlet, P., Denninger, M.-H., Vidaud, D., Condat, B., Hadengue, A., Primignani, M., Garcia-Pagan, J.-C., Janssen, H.L.A. & Valla, D. (2010) Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology, 51, 210-218.
104. Poort, S.R., Rosendaal, F.R., Reitsma, P.H. & Bertina, R.M. (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88, 3698-3703.
105. Prakash, S., Hoffman, R., Barouk, S., Wang, Y.L., Knowles, D.M. & Orazi, A. (2012) Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Modern Pathology, 25, 815-827.
106. Primignani, M., Martinelli, I., Bucciarelli, P., Battaglioli, T., Reati, R., Fabris, F., Dell'Era, A., Pappalardo, E. & Mannucci, P.M. (2005) Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology, 41, 603-608.
107. Primignani, M., Barosi, G., Bergamaschi, G., Gianelli, U., Fabris, F., Reati, R., Dell'Era, A., Bucciarelli, P. & Mannucci, P.M. (2006) Role of JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 44, 1528-1534.
108. Qi, X., Zhang, C., Han, G., Zhang, W., He, C., Yin, Z., Liu, Z., Bai, W., Li, R., Bai, M., Yang, Z., Wu, K. & Fan, D. (2012) Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chari syndrome and portal vein thrombosis: a prospective study. Journal of Gastroenterology and Hepatology, 27, 1036-1043.
109. Rajani, R., Melin, T., Bjornsson, E., Broomé, U., Sangfelt, P., Danielsson, A., Gustavsson, A., Grip, O., Svensson, H., Lööf, L., Wallerstedt, S. & Almer, S.H.C. (2009) Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival. Liver International, 29, 253-259.
110. Rajani, R., Bergquist, E.B.A., Danielsson, A., Gustavsson, A., Grip, O., Melin, T., Sangfelt, P., Wallerstedt, S. & Almer, S. (2010) The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Alimentary Pharmacology and Therapeutics, 32, 1154-1162.
111. Randi, M.L., Fossi, C., Fabris, F. & Girolami, A. (2000) State-of-the-art-review: essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy - a follow-up study in 68 patients. Clinical and Applied Thrombosis/Hemostasis, 6, 31-35.
112. Randi, M.L., Fabris, F., Ruzzon, E., Pacquola, E., Cella, G. & Girolami, A. (2002) Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Haematologica, 87, 1180-1184.
113. Rautou, P.E., Plessier, A., Bernuau, J., Denninger, M.H., Moucari, R. & Valla, D. (2009) Pregnancy: a risk factor for Budd-Chiari syndrome? Gut, 58, 606-608.
114. Regina, S., Herault, O., D'Alteroche, L., Binet, C. & Gruel, Y. (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 5, 859-861.
115. Reikvam, H. & Tiu, R.V. (2012) Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukaemia, 26, 563-571.
116. Riva, N., Donadini, M.P., Dentali, F., Squizzato, A. & Ageno, W. (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thrombosis Research, 130, S1-S3.
117. Rosti, V., Bonetti, E., Bergamaschi, G., Campanelli, R., Guglielmelli, P., Mastri, M., Magrini, U., Massa, M., Tinelli, C., Viarengo, G., Villani, L., Primignani, M., Vannucchi, A.M., Frassoni, F. & Barosi, G. (2010) High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS ONE, 5, e15277.
118. Rosti, V., Villani, L., Riboni, R., Poletto, V., Bonetti, E., Tozzi, L., Bergamaschi, G., Catarsi, P., Dallera, E., Novara, F., Massa, M., Campanelli, R., Fois, G., Peruzzi, B., Lucioni, M., Guglielmelli, P., Pancrazzi, A., Fiandrino, G., Zuffardi, O., Magrini, U., Paulli, M., Vannucchi, A.M. & Barosi, G. (2013) Spleen endothelial cells from patients with myelofibrosis harbor the JAK2 V617F mutation. Blood, 121, 360-368.
119. Ruiz-Tovar, J., Pérez de Oteyza, J., Sánchez, J.B., Velardo, A.A., Blando, R.R., Guirao, M.V.C. & Villanueva, A.G. (2007) Portal vein thrombosis after laparascopic splenectomy in benign hematologic diseases. Journal of Laparoendoscopic & Advanced Surgical Techniques, 17, 448-454.
120. Senzolo, M., Sartori, T.M., Rossetto, V., Burra, P., Cillo, U., Boccagni, P., Gasparini, D., Miotto, D., Simioni, P., Tsochatzis, E. & Burroughs, K.A. (2012) Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver International, 32, 919-927.
121. Shetty, S., Kulkarni, B., Pai, N., Mukundan, P., Kasatkar, P. & Ghosh, K. (2010) JAK2 mutations across a spectrum of venous thrombosis cases. American Journal of Clinical Pathology, 134, 82-85.
122. Smalberg, J.H., Murad, S.D., Braakman, E., Valk, P.J., Janssen, H.L.A. & Leebeek, F.W.G. (2006) Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica, 91, 1712-1713.
123. Smalberg, J.H., Koehler, E., Murad, S.D., Plessier, A., Seijo, S., Trebicka, J., Primignani, M., de Maat, M.P.M., Garcia-Pagan, J.-C., Valla, D.C., Janssen, H.L.A. & Leebeek, F.W.G. (2011) The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood, 117, 3968-3973.
124. Smalberg, J.H., Arends, L.R., Valla, D.C., Kildadjian, J.-J., Janssen, H.L.A. & Leebeek, F.W.G. (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood, 120, 4921-4928.
125. Sozer, S., Fiel, M.I., Schiano, T., Xu, M., Mascarenhas, J. & Hoffman, R. (2009) The presence of JAK2V617F of mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood, 113, 5246-5249.
126. Stein, B.L., Williams, D.M., Wang, N.-Y., Rogers, O., Isaacs, M.A., Pemmaraju, N., Spivak, J.L. & Moliterno, A.R. (2010) Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. Haematologica, 95, 1090-1097.
127. Stein, B.L., Saraf, S., Sobol, U., Halpern, A., Shammo, J., Damiano, R., Michaelis, L., Odenike, O., Rademaker, A., Zakarija, A., McMahon, B., Spivak, J.L. & Moliterno, A.R. (2013) Age-related differences in disease characteristics and clinical outcome in polycythemia vera. Leukemia & Lymphoma, doi: 10.3109/10428194.2012.759656.
128. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pilera, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
129. Tefferi, A. & Vardiman, J.W. (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukaemia, 22, 14-22.
130. Tefferi, A., Mesa, R.A., Nagorney, D.M., Schroeder, G. & Silverstein, M.N. (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood, 95, 2226-2233.
131. Teofili, L., Martini, M., Iachininoto, M.G., Capodimonti, S., Nuzzolo, E.R., Torti, L., Cenci, T., Larocca, L.M. & Leone, G. (2011) Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood, 117, 2700-2707.
132. Thatipelli, M.R., McBane, R.D., Hodge, D.O. & Wysokinski, W.E. (2010) Survival and recurrence in patients with splanchnic vein thromboses. Clinical Gastroenterology and Hepatology, 8, 200-205.
133. Trappenbug, M.C., van Schilfgaarde, M., Marchetti, M., Spronk, H.M., ten Cate, H., Leyte, A., Terpstra, W.E. & Falanga, A. (2009) Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica, 94, 911-918.
134. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V., Bogani, C., Ferrini, P.R., Rambaldi, A., Guerini, V., Bosi, A. & Barbui, T. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukaemia, 21, 1952-1959.
135. Van't Riet, M., Burger, J.W.A., van Muiswinkel, J.M., Kazemier, G., Schipperus, M.R. & Bonjer, H.J. (2000) Diagnosis and treatment of portal vein thrombosis following splenectomy. British Journal of Surgery, 87, 1229-1233.
136. Vecchio, R., Cacciola, E., Cacciola, R., Marchese, S. & Inagliata, E. (2011) Portal vein thrombosis after laparoscopic and open splenectomy. Journal of laparoendoscopic & advanced surgical techniques, 21, 71-75.
137. Villa, E., Camma, C., Marietta, M., Luongo, M., Critelli, R., Colopi, S., Tata, C., Zecchini, R., Gitto, S., Petta, S., Lei, B., Bernabucci, V., Vukotic, R., De Maria, N., Schepis, F., Karampatou, A., Caporali, C., Simoni, L., Del Buono, M., Zambotto, B., Turola, E., Fornaciari, G., Schianchi, S., Ferrari, A. & Valla, D. (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology, 143, 1253-1260. E4.
138. Villani, L., Bergamaschi, G., Primignani, M., Rosti, V., Carolei, A., Poletto, V., Catarsi, P., Spolverini, A., Vannucchi, A.M. & Barosi, G. (2012) JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leukemia Research, 36, e7-e9.
139. Wang, X., Prakash, S., Lu, M., Tripodi, J., Ye, F., Najfeld, V., Li, Y., Schwartz, M., Weinberg, R., Roda, P., Orazi, A. & Horrman, R. (2012) Spleens of myelofibrosis patients contain hematopoietic stem cells. The Journal of Clinical Investigation, 122, 3888-3899.
140. Wautier, M.P., El Nemer, W., Gane, P., Rain, J.D., Cartron, J.P., Colin, Y., Le Van Kim, C. & Wautier, J.L. (2007) Increased adhesion to endothelial cells of erythrocytes from patients with polycythaemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood, 110, 894-901.
141. Wehmeier, A., Daum, I. & Jamin, H. (1991) Schneider. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders: a retrospective analysis of 260 patients. Annals of Hematology, 63, 101-106.
142. Westbrook, R.H., Lea, N.C., Mohamedali, A.M., Smith, A.E., Orr, D.W., Roberts, L.N., Heaton, N.D., Wendon, J.A., O'Grady, J.G., Heneghan, M.A. & Mufti, G.J. (2012) Prevalence and clinical outcomes of the 46/1 haplotype, janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplant. Liver transplantation, 18, 819-827.
143. Winslow, E.R., Brunt, L.M., Drebin, J.B., Soper, N.J. & Klingensmith, M.E. (2002) Portal vein thrombosis after splenectomy. American Journal of Surgery, 184, 631-636.
144. Wolanskyj, A.P., Schwager, S.M., McClure, R.G., Larson, E.R. & Terreri, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81, 159-166.
145. Xavier, S.G., Gadelha, T., Pimenta, G., Eugenio, A.M., Ribeiro, D.D., Gomes, F.M., Bonamino, M., Zalcberg, I.R. & Spector, N. (2010) JAK2V617F mutation in patients with splanchnic vein thrombosis. Digestive diseases and sciences, 55, 1770-1777.
146. Zahn, A., Gotthardt, D., Weiss, K.H., Richter, G., Schmidt, J., Stremmel, W. & Sauer, P. (2010) Budd-Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt. BMC Gastroenterology, 10, 25.